Paragon 28, Inc. (NYSE:FNA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Paragon 28, Inc. (NYSE:FNA) have earned an average recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $15.60.

Several research firms recently commented on FNA. Needham & Company LLC reiterated a “buy” rating and issued a $13.00 price objective on shares of Paragon 28 in a research report on Monday, January 13th. William Blair lowered shares of Paragon 28 from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Stephens upgraded shares of Paragon 28 to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Canaccord Genuity Group decreased their price objective on shares of Paragon 28 from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

Paragon 28 Stock Performance

Shares of FNA opened at $12.00 on Wednesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.60 and a current ratio of 3.50. The stock has a market capitalization of $1.00 billion, a P/E ratio of -16.22 and a beta of 1.50. The company’s fifty day moving average is $10.45 and its two-hundred day moving average is $8.32. Paragon 28 has a 1 year low of $4.65 and a 1 year high of $14.79.

Paragon 28 (NYSE:FNA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The company had revenue of $62.30 million for the quarter, compared to analyst estimates of $60.58 million. Paragon 28 had a negative net margin of 25.31% and a negative return on equity of 37.90%. The business’s revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.10) EPS. On average, sell-side analysts predict that Paragon 28 will post -0.64 earnings per share for the current year.

Insider Buying and Selling at Paragon 28

In other Paragon 28 news, major shareholder Mvm Partners, Llc sold 20,136 shares of the company’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $11.63, for a total value of $234,181.68. Following the transaction, the insider now directly owns 10,366,009 shares in the company, valued at approximately $120,556,684.67. This represents a 0.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have sold 273,050 shares of company stock worth $2,819,696. Corporate insiders own 15.32% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of FNA. Renaissance Technologies LLC acquired a new position in shares of Paragon 28 during the 2nd quarter valued at about $419,000. Hsbc Holdings PLC acquired a new position in shares of Paragon 28 during the 2nd quarter valued at about $104,000. XTX Topco Ltd increased its stake in shares of Paragon 28 by 36.4% during the 2nd quarter. XTX Topco Ltd now owns 22,335 shares of the company’s stock valued at $153,000 after acquiring an additional 5,963 shares during the last quarter. Sei Investments Co. acquired a new position in shares of Paragon 28 during the 2nd quarter valued at about $531,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Paragon 28 during the 2nd quarter worth approximately $869,000. Institutional investors and hedge funds own 63.57% of the company’s stock.

Paragon 28 Company Profile

Paragon 28, Inc develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems.